Close menu

June 10th, 2022 | 11:48 CEST

BioNTech, NervGen Pharma, Valneva - Which stock will make the breakthrough in incurable diseases?

  • Biotechnology
Photo credits:

The number of cancer patients increases every year, and only if the disease is detected at an early stage might a cure still be possible. With other diseases such as multiple sclerosis or Alzheimer's, there is no chance of a cure at all. The deterioration progresses slowly and unstoppably. COVID-19 has also shown us how vulnerable humanity is to a virus. But many biotech companies have taken up the fight against these diseases. Any drug that can stop the progression of these diseases would help those affected. Many biotech stocks have corrected significantly recently. Today we take a look at three companies and their existing potential against incurable diseases.

time to read: 4 minutes | Author: Armin Schulz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , NERVGEN PHARMA CORP | CA64082X2032 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech - Positive results from oncology study

    BioNTech has become famous for its COVID-19 vaccine because the Mainz-based company was the first to succeed in developing a vaccine. Even today, the vaccine is the most popular in Germany. The Company not only deals with the Coronavirus, but also develops immunotherapies for the individual treatment of cancer and other infectious diseases. Thanks to the blockbuster Comirnaty, the Company is in a good financial position and can easily invest large sums in research and development. In addition, Corona has ensured that its mRNA technology is now recognized.

    The oncology pipeline is bulging with 16 product candidates in 20 ongoing clinical trials. Fittingly, there are positive Phase 1 data from the mRNA-based individualized neoantigen-specific immunotherapy in patients with pancreatic cancer, as announced by the Company on June 5. Prof. Özlem Türeci, MD, said she was pleased, "The early results of this Phase 1 study are encouraging, and we look forward to investigating it further in a larger randomized trial." However, the Corona vaccine continues to hold the greatest promise in the short term. In the US, it has filed jointly with Pfizer for approval in the 6 month to 5 year age group.

    A vaccine directed explicitly against the Omicron variant is expected to be launched soon. This could provide another boost to the share price in the short term. At the last quarterly figures, management had confirmed the forecast of EUR 13-17 billion in sales. Now that there are more and more new Omicron variants, the new vaccine could be in high demand. Despite the positive news, the share is no longer gaining momentum. Since March, the share has been running sideways between EUR 111.30 and EUR 170.00. It is, therefore, a long way from the 2021 highs at EUR 395.

    NervGen Pharma - Cure for nerve damage

    NervGen Pharma is focused on researching, developing and commercializing pharmaceutical products to treat nerve damage, including spinal cord injury, multiple sclerosis and Alzheimer's disease. These diagnoses all have one thing in common, the nerves are damaged and the body responds by scarring to contain the damage. But what makes sense at first inhibits nerve regeneration because the scar tissue contains chondroitin sulfate proteoglycan (CSPG). The Company has secured a license from Case Western Reserve University for NVG-291, a technology developed by Dr Jerry Silver. Dr Silver has been conducting research on repairing the patient's nervous system since the 1990s.

    The product candidate, NVG-291, is in clinical trials to treat spinal cord injury, multiple sclerosis and Alzheimer's disease. On May 12, the Company announced that it had received approval to administer the third and highest dose in the clinical trial. There were no serious adverse events in the second dose cohort. The dose was significantly higher than that used in preclinical animal studies, in which the drug has shown the potential to promote nervous system repair mechanisms. CEO Paul Brennan was pleased, saying, "This provides us with a clear pathway to define our dosing as we plan our upcoming Phase 1b/2a efficacy studies in patients with Alzheimer's disease and spinal cord injury later in 2022 and a Phase 2 study in patients with multiple sclerosis in early 2023."

    The experienced management team was expanded in April with the addition of Craig Thompson. He has more than 30 years of industry experience, primarily in drug development, which he can bring to bear on the upcoming Phase 1b/2 trials of NVG-291. If the breakthrough succeeds in the upcoming phase, the potential is enormous. There are about 6 million Alzheimer's patients in the US alone. The Company still wants to be listed on NASDAQ in 2022 to significantly increase its visibility. The stock, trading at 3.33 Canadian dollars (CAD) last November, is currently trading at CAD 1.90. The next support zones are at CAD 1.80 and CAD 1.61.

    Valneva - Vaccine against Chikungunya fever ready for the market

    Investors at Valneva are also thinking primarily of the Corona vaccine, which is still awaiting EU approval. But the vaccine company has more to offer than the Corona vaccine VLA2001. The French company specializes in the development and marketing of prophylactic vaccines against infectious diseases with a high unmet medical need. Together with its partner Pfizer, the Company is working on a Lyme disease vaccine candidate that, following a successful phase 2, is now entering the decisive phase 3 stage.

    One step further is the drug VLA1553, which has successfully completed Phase 3 and combats Chikungunya fever. This virus is transmitted by mosquitoes and is found mainly in warmer climates. Due to climate change, outbreaks have already occurred in southern Europe. The market is currently estimated at around USD 500 million, and Valneva currently holds a monopoly position, thus receiving accelerated approval in the USA and Europe.

    The European Medicines Agency has now accepted the application for approval of the Corona vaccine, but the Company does not have much time left to make improvements. If the Company obtains approval for the vaccine, the share price should break out of its sideways phase. This situation has persisted since mid-May and will dissipate in the coming days. If Valneva does not receive approval, the lows of EUR 9.15 will be attacked. A test of the upper side of the range at EUR 12.69 is likely if the approval is successful. It will be exciting.

    New technologies and research bring hope that even incurable diseases can be conquered or at least mitigated in the future. BioNTech is intensely active in the field of cancer and can already show first small successes. NervGen Pharma has already demonstrated in animals that its drug can heal nerve damage. If these results can be transferred to humans, it would be a milestone for many currently incurable diseases. Valneva has brought its vaccine against Chikungunya fever to market maturity. The stock could jump quickly if the Company receives EU approval for the Corona vaccine.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.